BioCardia Files 8-K: Other Events & Financials
Ticker: BCDA · Form: 8-K · Filed: Mar 12, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
BioCardia dropped an 8-K on 3/12. Check it for event and financial updates.
AI Summary
BioCardia, Inc. filed an 8-K on March 12, 2024, to report on other events and financial statements. The company, previously known as Tiger X Medical, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides updates on significant company events and financial reporting, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily reporting on other events and financial statements without immediate, significant operational or financial news.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- March 12, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 12, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 12, 2024.
What was BioCardia, Inc. previously known as?
BioCardia, Inc. was previously known as Tiger X Medical, Inc.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What is BioCardia, Inc.'s Standard Industrial Classification code?
BioCardia, Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-03-12 07:00:17
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240312_8k.htm (8-K) — 30KB
- ex_637952.htm (EX-99.1) — 11KB
- 0001437749-24-007371.txt ( ) — 190KB
- bcda-20240312.xsd (EX-101.SCH) — 4KB
- bcda-20240312_def.xml (EX-101.DEF) — 13KB
- bcda-20240312_lab.xml (EX-101.LAB) — 17KB
- bcda-20240312_pre.xml (EX-101.PRE) — 13KB
- bcda20240312_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 12, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the Centers for Medicare and Medicaid Services has approved reimbursement coverage for the confirmatory Phase III clinical trial of the CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure (the CardiAMP Heart Failure II Trial).
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: March 12, 2024